Stocktoria
aTYR PHARMA INC ATYR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2015-05-07
aTYR PHARMA INC statistics & valuation
Market cap$51.7M
P / B0.8×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -40856.3% | -28899.6% | -15557.8% | -446.8% | — |
| Net margin | -39009.5% | -27243.8% | -14274.5% | -436.5% | — |
| FCF margin | -32664.7% | -29440.0% | -10605.1% | -419.1% | — |
| Return on assets | -79.7% | -66.1% | -41.8% | -47.3% | -29.2% |
| Return on equity | -109.8% | -91.4% | -55.6% | -63.4% | -30.9% |
| Current ratio | 5.30 | 5.48 | 6.27 | 5.83 | 18.89 |
| Revenue growth | -19.1% | -33.4% | -96.6% | — | -100.0% |
Source: SEC EDGAR filings · CIK 0001339970 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.